Filing exhibits
- 8-K Current report
- 2.1 Agreement and Plan of Merger, Dated As of July 25, 2022, by and Among Somalogic, Merger Sub I, Merger Sub II, Palamedrix, and the Securityholder Representative
- 99.1 SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan® Assay
- Download Excel data file
- View Excel data file
Table of Contents